An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02473289 |
Recruitment Status :
Completed
First Posted : June 16, 2015
Results First Posted : June 11, 2019
Last Update Posted : June 11, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Depressive Disorder, Major | Drug: Sirukumab 50 mg Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 193 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a Monoaminergic Antidepressant in Adults With Major Depressive Disorder |
Actual Study Start Date : | July 23, 2015 |
Actual Primary Completion Date : | May 22, 2018 |
Actual Study Completion Date : | May 22, 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Sirukumab 50 milligram (mg)
Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
|
Drug: Sirukumab 50 mg
Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56. |
Placebo Comparator: Placebo
Participants will receive matching placebo on Day 1, 28 and 56.
|
Drug: Placebo
Participants will receive matching placebo on Day 1, 28 and 56. |
- Change From Baseline in Hamilton Depression Rating Scale (HDRS-17) Total Score at Week 12 [ Time Frame: Baseline and Week 12 ]The HDRS-17 is a clinician-administered rating scale designed to assess the severity of symptoms in participants diagnosed with depression with a score range of 0 to 52. Each of the 17 items is rated by the clinician on either a 3-point (0 to 2) or a 5-point scale (0 to 4). The point scale used a rating of 0 (absent), 1 (doubtful to mild), 2 (mild to moderate), 3 (moderate to severe), and 4 (very severe). A total score (0 to 52) was calculated by adding the scores of all 17 items. For each item as well as the total score, a higher score represents a more severe condition. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.
- Change From Baseline in HDRS-17 Total Score at Weeks 1, 4 and 8 [ Time Frame: Baseline, Weeks 1, 4 and 8 ]The HDRS-17 is a clinician-administered rating scale designed to assess the severity of symptoms in participants diagnosed with depression with a score range of 0 to 52. Each of the 17 items is rated by the clinician on either a 3-point (0 to 2) or a 5-point scale (0 to 4). The point scale used a rating of 0 (absent), 1 (doubtful to mild), 2 (mild to moderate), 3 (moderate to severe), and 4 (very severe). A total score (0 to 52) was calculated by adding the scores of all 17 items. For each item as well as the total score, a higher score represents a more severe condition.
- Percentage of Participants With Remission as Assessed by HDRS-17 Total Score at Week 12 [ Time Frame: Week 12 ]Remission- Percentage of participants with HDRS-17 total score less than or equal to (<=) 7 were considered as remitters. HDRS-17 defined as clinician-administered rating scale designed to assess severity of symptoms in participants diagnosed with depression with score range of 0 to 52. Each of 17 items is rated by clinician on either a 3-point (0 to 2) or a 5-point scale (0 to 4). The point scale used a rating of 0 (absent), 1 (doubtful to mild), 2 (mild to moderate), 3 (moderate to severe), and 4 (very severe). A total score (0 to 52) was calculated by adding scores of all 17 items. For each item as well as total score, a higher score represents a more severe condition.
- Percentage of Participants With Response as Assessed by HDRS-17 Total Score at Week 12 [ Time Frame: Week 12 ]Response- Percentage of participants with greater than or equal to (>=) 50 percent (%) improvement on the HDRS-17 total score from baseline at Week 12 were considered as responders. The HDRS-17 defined as clinician-administered rating scale designed to assess the severity of symptoms in participants diagnosed with depression with a score range of 0 to 52. Each of the 17 items is rated by the clinician on either a 3-point (0 to 2) or a 5-point scale (0 to 4). The point scale used a rating of 0 (absent), 1 (doubtful to mild), 2 (mild to moderate), 3 (moderate to severe), and 4 (very severe). A total score (0 to 52) was calculated by adding the scores of all 17 items. For each item as well as the total score, a higher score represents a more severe condition.
- Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Score at Weeks 1, 4, 8, 12, 16, and 22 [ Time Frame: Baseline and Weeks 1, 4, 8, 12, 16, and 22 ]CGI-S defined as clinician-rated scale that assesses the severity of mental illness on a scale of 0 to 7. Considering total clinical experience, a participant was assessed on severity of mental illness at the time of rating according to:1: normal, not at all ill; 2: borderline mentally ill; 3: mildly ill; 4: moderately ill; 5: markedly ill; 6: severely ill; 7: among the most extremely ill patients. A higher score implies a more severe condition.
- Change From Baseline in Patient Health Questionnaire (PHQ-9) Total Score at Weeks 1, 4, 8, 12, 16, and 22 [ Time Frame: Baseline and Weeks 1, 4, 8, 12, 16, and 22 ]The PHQ-9 used as a participant-reported measure of depressive symptomatology. The PHQ-9 is 9-item scale, where each item is rated on a 4-point scale (0=Not at all, 1=Several Days, 2=More than half the days, and 3=Nearly every day). The participant's item responses were summed to provide a total score range of 0 to 27. Higher scores indicates greater severity of depressive symptoms. The recall period is 2 weeks.
- Change From Baseline in Snaith Hamilton Pleasure Scale (SHAPS) Total Score (Definition 1) at Weeks 1, 4, 8, 12, 16, and 22 [ Time Frame: Baseline and Weeks 1, 4, 8, 12, 16, and 22 ]The Snaith-Hamilton Pleasure Scale (SHAPS) is short, 14-item instrument to measure anhedonia. Each of the 14 items has a set of four response categories (Definition 1): Definitely Agree (=1), Agree (= 2), Disagree (= 3), and Definitely Disagree (= 4). A SHAPS total score was calculated as the sum of the 14 item scores with a total score range from 14 to 56. A higher total score indicates higher levels of state anhedonia.
- Change From Baseline in Snaith Hamilton Pleasure Scale (SHAPS) Total Score (Definition 2) at Weeks 1, 4, 8, 12, 16, and 22 [ Time Frame: Baseline and Weeks 1, 4, 8, 12, 16, and 22 ]The Snaith-Hamilton Pleasure Scale (SHAPS) is short, 14-item instrument to measure anhedonia. Each of the 14 items has a set of four response categories (Definition 2): Definitely Agree (= 0), Agree (= 0), Disagree (= 1), and Definitely Disagree (= 1). A SHAPS total score was calculated as the sum of the 14 item scores with a score range from 0 to 14. A higher total score indicates higher levels of state anhedonia.
- Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Total Score at Weeks 1, 4, 8, 12, 16, and 22 [ Time Frame: Baseline and Weeks 1, 4, 8, 12, 16, and 22 ]The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores [4 - score] for all except for 2 items: "I have energy" and "I am able to do my usual activities"), and ranges from 0 to 52, with a higher score indicating less fatigue.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 64 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participants must have a primary DSM-5 diagnosis of MDD
- Must have a HDRS total score greater than or equal to (>=) 18 at screening and predose at Day 1, as recorded by the remote independent rater and must not demonstrate an improvement of > 25 percent (%) on their HDRS total score from the screening to baseline visit
- Must be medically stable on the basis of physical examination, medical history, vital signs, clinical laboratory tests and 12-lead ECG performed at screening. If there are abnormalities, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the subject's source documents and initialed by the investigator
- Participants with hypothyroidism who are on stable treatment for 3 months prior to screening are required to have thyroid stimulating hormone (TSH) and free thyroxine (FT4) obtained. If the TSH value is out of range, but FT4 is normal, such cases should be discussed directly with the medical monitor before the subject is enrolled. If the FT4 value is out of range, the participant is not eligible
Exclusion Criteria:
- Any other current Axis one psychiatric condition, including, but not limited to, MDD with current psychotic features, bipolar disorder (including lifetime diagnosis), obsessive-compulsive disorder, borderline personality disorder, eating disorder (eg, bulimia, anorexia nervosa), or schizophrenia (lifetime). The MINI will be used to screen for comorbid psychiatric diagnoses. As noted above, subjects with a diagnosis of comorbid GAD, Post-Traumatic Stress Disorder, Persistent Depressive Disorder, ADHD, Social Anxiety Disorder, Panic Disorder with or without agoraphobia or Nicotine/Caffeine Dependence may be included, if the investigator considers MDD to be the primary diagnosis
- A history of alcohol or substance use disorder (abuse/dependence) within 6 months prior to screening (nicotine and caffeine dependence are not exclusionary)
- A current or recent (within the past year) history of clinically significant suicidal ideation (corresponding to a score of >= 3 for ideation) or any suicidal behavior within the past year, as validated on the C-SSRS at screening or baseline. Subjects with a prior suicide attempt of any sort, or history of prior serious suicidal ideation/plan should be carefully screened for current suicidal ideation and only included at the discretion of the investigator
- More than 3 failed antidepressant treatments (of adequate dose and duration) in the current episode of depression (verified by the MGH-ATRQ)
- Length of current major depressive episode > 60 months

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02473289
United States, Alabama | |
Birmingham, Alabama, United States | |
United States, Arkansas | |
Little Rock, Arkansas, United States | |
United States, California | |
Bellflower, California, United States | |
Glendale, California, United States | |
Lemon Grove, California, United States | |
Orange, California, United States | |
Santa Ana, California, United States | |
Torrance, California, United States | |
Wildomar, California, United States | |
United States, Georgia | |
Atlanta, Georgia, United States | |
Decatur, Georgia, United States | |
United States, Illinois | |
Chicago, Illinois, United States | |
United States, Kentucky | |
Edgewood, Kentucky, United States | |
United States, Maryland | |
Baltimore, Maryland, United States | |
United States, Michigan | |
Grand Rapids, Michigan, United States | |
United States, New Hampshire | |
Lebanon, New Hampshire, United States | |
United States, New York | |
Brooklyn, New York, United States | |
New York, New York, United States | |
Staten Island, New York, United States | |
United States, Ohio | |
Columbus, Ohio, United States | |
United States, Oklahoma | |
Oklahoma City, Oklahoma, United States | |
United States, Texas | |
Houston, Texas, United States | |
Plano, Texas, United States | |
United States, Utah | |
Salt Lake City, Utah, United States | |
Canada, Alberta | |
Edmonton, Alberta, Canada | |
Canada, Ontario | |
Chatham, Ontario, Canada | |
Hamilton, Ontario, Canada | |
Toronto, Ontario, Canada | |
Poland | |
Belchatow, Poland | |
Bydgoszcz, Poland | |
Chelmno, Poland | |
Gorlice, Poland | |
Lublin, Poland | |
Russian Federation | |
Karelia, Russian Federation | |
Moscow, Russian Federation | |
Nizny Novgorod, Russian Federation | |
Rostov-on-Don, Russian Federation | |
Saratov Region, Russian Federation | |
Saratov, Russian Federation | |
St-Petersburg, Russian Federation | |
Tomsk, Russian Federation | |
Yaroslavl, Russian Federation | |
United Kingdom | |
Edinburgh, United Kingdom | |
Glasgow, United Kingdom | |
Oxford, United Kingdom | |
Redruth, United Kingdom |
Study Director: | Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC |
Documents provided by Janssen Research & Development, LLC:
Responsible Party: | Janssen Research & Development, LLC |
ClinicalTrials.gov Identifier: | NCT02473289 |
Other Study ID Numbers: |
CR107171 CNTO136MDD2001 ( Other Identifier: Janssen Research & Development, LLC ) 2014-005206-37 ( EudraCT Number ) |
First Posted: | June 16, 2015 Key Record Dates |
Results First Posted: | June 11, 2019 |
Last Update Posted: | June 11, 2019 |
Last Verified: | May 2019 |
Studies a U.S. FDA-regulated Device Product: | No |
Depressive disorder, major Sirukumab |
Disease Depressive Disorder Depression Depressive Disorder, Major |
Pathologic Processes Mood Disorders Mental Disorders Behavioral Symptoms |